Drug Trial Radar · NCT04201457
A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration
Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
57
Actual
Start
Jan 17, 2020
Primary completion
Oct 1, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Pediatric Brain Tumor ConsortiumResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI); American Lebanese Syrian Associated Charities
- First posted
- Dec 17, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year, up to 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I/II trial is designed to study the side effects, best dose and efficacy of adding hydroxychloroquine to dabrafenib and/or trametinib in children with low grade or high grade brain tumors previously treated with similar drugs that did not respond completely (progressive) or tumors that came back while receiving a similar agent (recurrent). Patients must also have specific genetic mutations including BRAF V600 mutations or BRAF fusion/duplication, with or without neurofibromatosis type 1. Neurofibromatosis type 1 is an inherited genetic condition that causes tumors to grow on nerve tissue. Hydroxychloroquine, works in different ways to stop the growth of tumor cells by killing the cells or stopping them from dividing. Trametinib and dabrafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving hydroxychloroquine with trametinib and/or dabrafenib may lower the chance of brain tumors growing or spreading compared to usual treatments.
Conditions
- Low Grade Glioma (LGG) of Brain With BRAF Aberration
- High Grade Glioma (HGG) of the Brain With BRAF Aberration
- Low Grade Glioma of Brain With Neurofibromatosis Type 1
Interventions
DabrafenibDrug
Dabrafenib capsule; Dabrafenib Dispersible Tablet
TrametinibDrug
Tablet; Powder for Oral Solution
HydroxychloroquineDrug
Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated Dose (MTD)/ Recommended Phase 2 Dose (RP2D)Time frame: Approximately 28 days from start of therapy
- Maximum Plasma ConcentrationTime frame: 1-4 days
- Area under the curve (AUC)Time frame: 1-4 days
- Phase II: Sustained objective response rate.Time frame: Up to approximately 2 years from the start of therapy
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Phoenix Children's Hospital
Phoenix, Arizona
Children's Hospital Los Angeles
Los Angeles, California
Lucile Packard Children's Hospital at Stanford University Medical Center
Palo Alto, California
Children's Hospital Colorado
Aurora, Colorado
Children's National Medical Center
Washington D.C., District of Columbia
University of Florida
Gainesville, Florida
Children's Healthcare of Atlanta
Atlanta, Georgia
Lurie Children's Hospital-Chicago
Chicago, Illinois
National Cancer Institute Pediatric Oncology Branch
Bethesda, Maryland
Memorial Sloan Kettering Cancer Center
New York, New York
Cincinnati Children Hospital Medical Center
Cincinnati, Ohio
Nationwide Children's Hospital
Columbus, Ohio
Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania
St. Jude Children Research Hospital
Memphis, Tennessee
Texas Children's Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.